title: Current systemic therapies for psoriasis: where are we now?
abstract: Many systemic agents are used in the treatment of psoriasis. They provide good control of psoriasis in the majority of patients and have improved their life quality indices. Frequently, combination therapy is utilized to synergize the efficacy of these medications. Many dermatologists are hesitant in prescribing systemic agents because of their adverse effects. However, such potential toxicities arising from these medications can largely be avoided if proper patient selection and close monitoring are performed.
authors.affiliation: Clinical Research Specialists, UCLA School of Medicine, 2001 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Yamauchi
authors.forename: Dalia
authors.initials: D
authors.lastname: Rizk
authors.forename: Tanya
authors.initials: T
authors.lastname: Kormeili
authors.forename: Rickie
authors.initials: R
authors.lastname: Patnaik
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Lowe
mesh_terms: D017255:Acitretin / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D007641:Keratolytic Agents; D016572:Cyclosporine; D017255:Acitretin; D006918:Hydroxyurea; D008727:Methotrexate